Triple therapy takes on aggressive blood cancer
NCT ID NCT05672173
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether adding a personalized cell therapy (liso-cel) to two existing drugs (nivolumab and ibrutinib) can help people with Richter's transformation, a rare and aggressive blood cancer. The study plans to enroll 9 participants and will measure how many achieve a complete response. It is still early, so the main goals are to check safety and see if the combination is promising enough for larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lisocabtagene maraleucel (a CAR T-cell therapy made from the patient's own immune cells), nivolumab (an immunotherapy drug), and ibrutinib (a targeted cancer pill)
What this could lead to
If this combination works, it could offer a new treatment option for people with Richter's transformation, a very aggressive blood cancer.
What could go wrong
This is a very small, early-phase trial with only 9 participants, so results may not apply to everyone. The combination therapy also carries risks of serious side effects, including immune system overreactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States